Lifecore Biomedical's Intergel
This article was originally published in The Gray Sheet
Executive Summary
Adhesion prevention solution shows 54% reduction (p=0.004) of adhesion formation in the abdominal cavities of 50 female laparoscopic abdominal surgery patients in a pilot clinical trial, the company tells investors at a June 9 session of the Piper Jaffray conference in Minneapolis. Twenty four abdominal sites are included as primary endpoints. The company expects to meet with FDA in the next month to finalize enrollment criteria to commence a pivotal laparoscopy study. Intergel was introduced in Europe May 5 by exclusive worldwide distributor Johnson & Johnson's Ethicon. U.S. sales are expected to begin in late 1999